EpiBone Secures Funding to Expand Clinical Trials Globally
Deal News | Nov 08, 2024 | EMV Capital
EpiBone, Inc., a leading figure in regenerative medicine focused on skeletal repair, has concluded a convertible note funding round spearheaded by Kendall Capital Partners. This round also saw participation from Lifespan Vision Ventures and EMV Capital plc, among others. The funds are earmarked for enhancing EpiBone's pipeline development and accelerating its mission of transforming skeletal reconstruction, aiming to expand clinical trials particularly in medical tourism hubs such as Thailand and the United Arab Emirates. Dr. Nina Tandon, CEO of EpiBone, emphasized the ongoing support from strategic investors as crucial in revolutionizing skeletal repair through science. David Zhu of Kendall Capital Partners and Dr. Ilian Iliev of EMV Capital highlighted EpiBone's innovative approach and potential impact on healthcare. EpiBone specializes in treatments involving autologous and allogeneic stem cells, 3D bioprinting, and bioreactor technology, aiming to redefine musculoskeletal treatment standards.
Sectors
- Regenerative Medicine
- Biotechnology
- Investment
Geography
- United States – EpiBone is based in New York, and the funding announcement was made there.
- Thailand – EpiBone is exploring clinical trials in Thailand, a rising hub for medical tourism.
- United Arab Emirates – The UAE is highlighted as another location for EpiBone's potential expansion of clinical trials in its global strategy.
Industry
- Regenerative Medicine – The article focuses on EpiBone's innovations in regenerative medicine, particularly in skeletal repair and reconstruction.
- Biotechnology – EpiBone's use of 3D bioprinting and bioreactor technology places the company in the biotechnology sector.
- Investment – The article discusses a convertible note funding round involving various private equity and venture capital participants.
Financials
- Not specified – The article announces the successful close of a convertible note funding round but does not specify the amount.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| EpiBone, Inc. | Target | Company | A regenerative medicine company focused on skeletal repair technology. |
| Kendall Capital Partners | Lead Investor | Company | The lead investor in EpiBone's funding round, supporting its global clinical trials. |
| EMV Capital plc | Investor | Company | A participant in the funding round continuing their support of EpiBone. |
| Lifespan Vision Ventures | Investor | Company | Another strategic participant in EpiBone's funding round. |
| Dr. Nina Tandon | CEO and Co-Founder | Person | CEO and Co-Founder of EpiBone, emphasizing the impact of the investment. |
| David Zhu | Founding Partner | Person | Founding Partner of Kendall Capital Partners, leading the investment round. |
| Dr. Ilian Iliev | CEO | Person | CEO of EMV Capital plc, praising EpiBone's innovative approach. |